8-KLeadership ChangesSecurities & Listing

Medtronic plc 8-K Report, Unregistered Securities Sale (Jan 15, 2015)

Filed January 15, 2015For Securities:MDT

Summary

This Form 8-K filing from Medtronic plc, filed on January 15, 2015, provides updates related to minor corporate actions and the ongoing, significant acquisition of Covidien plc. Notably, the company alloted Euro Deferred Shares to existing shareholders via a private placement, an action taken in reliance on an exemption from registration under the Securities Act of 1933. Additionally, the filing reports the resignation of a Board Director, Robert ten Hoedt, and the appointment of Gerard Kilcommins as a new director. Mr. Kilcommins' appointment is temporary, expected to conclude before the Covidien acquisition closes, and he will not receive separate compensation for his director role. Investors should note that these events are presented within the context of Medtronic's major acquisition of Covidien. The filing emphasizes the importance of the Joint Proxy Statement/Prospectus related to this acquisition, urging shareholders to review these documents for comprehensive information regarding the transaction, which was declared effective by the SEC. This 8-K, therefore, serves as a procedural update alongside the critical information flow concerning the transformative Covidien deal.

Key Highlights

  • 1Medtronic allotted 39,993 Euro Deferred Shares to existing shareholders for €39,993.00 in a private placement.
  • 2The issuance of Euro Deferred Shares was conducted under an exemption from registration, pursuant to Section 4(a)(2) of the Securities Act of 1933.
  • 3Robert ten Hoedt resigned from the Board of Directors on January 9, 2015, with no disagreement cited.
  • 4Gerard Kilcommins, an employee, was appointed to the Board of Directors on January 9, 2015.
  • 5Mr. Kilcommins' tenure as a director is temporary and expected to end prior to the closing of the Covidien acquisition.
  • 6Mr. Kilcommins will not receive additional compensation for his director services, beyond his employee compensation.
  • 7The filing reiterates the importance of the Joint Proxy Statement/Prospectus concerning the acquisition of Covidien plc.

Frequently Asked Questions

The issuance of Euro Deferred Shares is a minor corporate action involving the allotment of shares to existing shareholders for nominal cash consideration. It was conducted as a private placement under an exemption from SEC registration, suggesting it was a private transaction not intended for broad public offering at that time.

Robert ten Hoedt resigned from the Board of Directors on January 9, 2015. The filing explicitly states that his resignation was not due to any disagreement with the company regarding its operations, policies, or practices.

Gerard Kilcommins, an employee of Medtronic, was appointed to the Board of Directors. His appointment is temporary and is expected to conclude before the acquisition of Covidien plc is completed. He will not receive separate compensation for his director duties.

This filing provides procedural updates and minor corporate actions. However, it also strongly emphasizes the ongoing, major acquisition of Covidien plc. Investors are directed to read the Joint Proxy Statement/Prospectus for critical information regarding this significant transaction.